Ani Pharmaceuticals (ANIP) Net Margin (2011 - 2026)

Ani Pharmaceuticals has disclosed Net Margin across 16 years of filings, most recently posting 12.42% for Q1 2026.

• Net Margin for Q1 2026 came in at 12.42%, up 467.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 9.89% (up 1326.0% YoY), and the FY2025 annual result was 8.74%, up 1202.0% from the prior year.
• Net Margin came in at 12.42% for Q1 2026 at Ani Pharmaceuticals, up from 11.13% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 12.95% in Q1 2024 to a low of 31.85% in Q1 2022.
• The 5-year median for Net Margin is 0.97% (2023), against an average of 1.12%.
• Peak annual rise in Net Margin reached 3499 bps in 2022, while the deepest fall reached 3257 bps in 2022.
• Ani Pharmaceuticals' Net Margin stood at 4.93% in 2022, then soared by 112 bps to 0.57% in 2023, then slumped by 1085 bps to 5.61% in 2024, then surged by 299 bps to 11.13% in 2025, then rose by 12 bps to 12.42% in 2026.
• The last three Net Margin figures came in at 12.42% (Q1 2026), 11.13% (Q4 2025), and 11.53% (Q3 2025), per Business Quant data.